| Autor: |
Ravindra Majeti, Christian C. Fritz, Jakob Lovén, David A. Orlando, Matthew G. Guenther, Kathryn Austgen, Julie L. Koenig, Steven M. Chan, Darren Smith, Mei Wei Chen, Jeremy T. Lopez, Emily Lee, Chris Fiore, Matthew L. Eaton, M. Ryan Corces, Michael R. McKeown |
| Rok vydání: |
2023 |
| DOI: |
10.1158/2159-8290.22531181.v1 |
| Popis: |
Supplementary Figure S1. Identification and refinement of cancer-specific super-enhancers in human AML. Supplementary Figure S2. Mapping of super-enhancers to genes. Supplementary Figure S3. AML SE profiles show pronounced variation in enhancers related to myeloid differentiation and enable de novo stratification into six distinct epigenomic subgroups. Supplementary Figure S4. Recapitulation of SE-defined clusters in AML data from the TCGA. Supplementary Figure S5 An SE is present at the RARA locus in a subset of AML samples. Supplementary Figure S6 SY-1425 is a selective and potent RARα agonist. Supplementary Figure S7 Comparison of SY-1425 response to RARA expression and enhancer score and the effect of an RARα antagonist. Supplementary Figure S8 SY-1425 in vivo pharmacokinetics. Supplementary Figure S9 SY-1425 survival and tissue effects on AML PDX models. Supplementary Figure S10 SY-1425 shows greater potency than ATRA in vitro and in vivo. Supplementary Figure S11 Induction of markers of myeloid differentiation in RARA-high AML cell lines upon SY-1425 treatment. Supplementary Figure S12 Comparison of SY-1425 expression and molecular response to APL. Supplementary Figure S13 SY-1425 expression and molecular response. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
